AstraZeneca Pharma India
NSE: ASTRAZEN · ISIN INE203A01020 · Healthcare
₹6,429.00−50.50 (−0.78%)
Monday 9 November, 13:07 IST. Delayed. Source: Yahoo Finance.
Price chart
₹6,429.00 −50.50 (−0.78%) today
The day
- Previous close
- ₹6,479.50
- Open
- ₹6,480.00
- Day high
- ₹6,485.50
- Day low
- ₹6,401.00
Listed on NSE since 4 May 2001.
Key numbers
- Market value
- ₹16,199 Cr
- P/E (trailing)
- 91.15
- EPS (trailing)
- ₹71.09
- Price to book
- 18.43
- Dividend yield
- 0.56%
- Return on equity
- 21.2%
- Debt to equity
- 0.11
- Profit margin
- 6.8%
- Beta
- 0.22
- Volume today
- 2,104
- Average volume
- 11,734
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹1,002.97 Cr | ₹99.29 Cr |
| FY24 | ₹1,295.53 Cr | ₹161.51 Cr |
| FY25 | ₹1,713.29 Cr | ₹115.74 Cr |
| FY26 | ₹2,272.58 Cr | ₹187.52 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹729 Cr | ₹62 Cr | +15.0% |
| Q1 FY27Apr–Jun 2026 | ₹683 Cr | ₹38 Cr | −32.1% |
| Q4 FY26Jan–Mar 2026Audited | ₹579 Cr | ₹45 Cr | −23.0% |
| Q3 FY26Oct–Dec 2025 | ₹612 Cr | ₹33 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹559 Cr | ₹54 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹526 Cr | ₹56 Cr | – |
Source: AstraZeneca Pharma India’s results filed with NSE, standalone (the company alone). Net profit is the share of AstraZeneca Pharma India’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 | March 2026 |
|---|---|---|
| Fixed assets | ₹115 Cr | ₹117 Cr |
| Inventories | ₹1,035 Cr | ₹1,027 Cr |
| Owed by customers | ₹285 Cr | ₹214 Cr |
| Cash and equivalents | ₹574 Cr | ₹448 Cr |
| Total assets | ₹2,191 Cr | ₹1,989 Cr |
| Borrowings | ₹0 | ₹0 |
| Total liabilities | ₹1,312 Cr | ₹1,116 Cr |
| Shareholders’ equity | ₹879 Cr | ₹873 Cr |
Source: AstraZeneca Pharma India’s half-yearly statements of assets and liabilities filed with NSE, standalone. Companies file these every September and March.
About AstraZeneca Pharma India
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cancers, including pancreatic cancer, certain blood cancers, and cancers within breast, lung, ovary, and prostate; rare diseases; and cardiovascular, renal and metabolism, and respiratory and immunology, as well as diabetes. The company serves distributors, hospitals, and government institutions. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Bengaluru
- Employees
- 760
Company website · Profile: Yahoo Finance
In the news
All newsDividends and corporate actions
All companies- Dividend - Rs 36 Per Share
Dividend · ex-date 31 July 2026
- Dividend - Rs 32 Per Share
Dividend · ex-date 18 July 2025
- Dividend - Rs 24 Per Share
Dividend · ex-date 5 July 2024
- Dividend - Rs 16 Per Share
Dividend · ex-date 14 July 2023
- Dividend - Rs 8 Per Share
Dividend · ex-date 7 July 2022 · record date 8 July 2022
- Interim Dividend - Rs 2 Per Share
Dividend · ex-date 18 August 2021 · record date 20 August 2021
- Interim Dividend - Rs 2 Per Share
Dividend · ex-date 20 August 2020 · record date 21 August 2020
- Interim Dividend - Re 1 Per Share
Dividend · ex-date 20 August 2019 · record date 21 August 2019
Source: NSE. Latest first, 8 of 20.
Information only, not investment advice. Prices are delayed.